Hodges Capital Management Inc. Increases Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Hodges Capital Management Inc. grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 3.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 332,954 shares of the biopharmaceutical company’s stock after acquiring an additional 12,410 shares during the period. Hodges Capital Management Inc. owned about 0.26% of Halozyme Therapeutics worth $15,919,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in HALO. Heck Capital Advisors LLC acquired a new position in Halozyme Therapeutics during the fourth quarter worth $29,000. GAMMA Investing LLC raised its holdings in shares of Halozyme Therapeutics by 67.7% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 350 shares during the period. Toth Financial Advisory Corp acquired a new position in Halozyme Therapeutics during the 3rd quarter worth about $57,000. FSC Wealth Advisors LLC purchased a new position in Halozyme Therapeutics during the 3rd quarter valued at about $65,000. Finally, Park Place Capital Corp grew its position in Halozyme Therapeutics by 828.1% in the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock valued at $78,000 after acquiring an additional 1,209 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $56.64 on Monday. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53. The stock has a market cap of $7.21 billion, a PE ratio of 18.76, a price-to-earnings-growth ratio of 0.43 and a beta of 1.25. The firm has a fifty day moving average price of $50.65 and a 200 day moving average price of $54.32.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. HC Wainwright upped their target price on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, January 10th. Wells Fargo & Company decreased their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, JMP Securities increased their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $60.89.

Insider Activity

In other news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares of the company’s stock, valued at $2,180,986.11. The trade was a 18.65 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 2.70% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.